Perrigo Board unanimously rejects unsolicited US$29bn bid from Mylan

Published: 22-Apr-2015
Finance

Says it substantially undervalues the company and ignores key factors


Perrigo said its Board of Directors has unanimously rejected the unsolicited takeover bid from Mylan, saying it 'substantially undervalues the company and its future growth prospects'.

Earlier this month Mylan offered to buy Perrigo for $205 per share in cash and stock.

Joseph Papa, Chairman, President and CEO of Perrigo, said Mylan had not taken key factors into account, including its global distribution platform, innovative new product pipeline, which is expected to generate nearly $1bn in net sales over the next three years, and the full benefits of the Omega Pharma acquisition, which closed on 30 March.

  • Companies:
  • Perrigo
See more

You may also like

Media

Hikma enters into licensing partnership with Perrigo in MENA

Read more
The partnership will provide significant collaboration opportunity

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Hikma enters into licensing partnership with Perrigo in MENA

The partnership will provide significant collaboration opportunity
Finance

Mylan fails in US$26bn hostile takeover bid for Perrigo

Not enough shareholders supported the deal
Finance

Perrigo to acquire OTC brands from GSK

In the areas of nicotine replacement therapy, cold and flu, and cold sore management
Drug Delivery

Perrigo acquires Patheon's Mexican operations for US$34m

Strengthening its capabilities with the addition of softgel manufacturing technology
Finance

Mylan offers to buy Perrigo for US$29bn

The combination would have 'critical mass' in speciality brands, generics, OTC and nutritional products
Finance

Perrigo to purchase Omega Pharma for €3.6bn

Expanding its over-the-counter product portfolio
Finance

Perrigo to buy Elan for US$8.6bn

Will form a new company incorporated in Ireland to be called Perrigo Company plc or a variant thereof
Subscribe now